Location History:
- Boochun-shi, Kyungki-do, KR (1997)
- Nowon-gu, Seoul, KR (2005)
- Daegu, KR (2016)
- Gyeonggi-do, KR (2019)
Company Filing History:
2 out of 337 
1 out of 68 
2 out of 832,880 Years Active: 1997-2025
Title: Innovations of Jung Min Kim in Antibacterial Treatments
Introduction
Jung Min Kim is a prominent inventor based in Daegu, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of methods for treating pathogenic bacterial infectious diseases. With a total of 6 patents to his name, his work focuses on innovative solutions to combat antibiotic-resistant bacteria.
Latest Patents
One of Jung Min Kim's latest patents is a method of treating pathogenic bacterial infectious diseases. This invention involves a pharmaceutical composition that includes a LysSAP26 protein, which is a recombinant protein derived from the bacteriophage genome. The active ingredient is administered to a subject to prevent or treat these infectious diseases. Another notable patent is the use of a recombinant antibacterial protein called Ablysin. This protein effectively kills multidrug-resistant pathogenic bacteria and can be utilized in various industries, including pharmaceuticals and food production. Ablysin works by degrading peptidoglycan, a component of bacterial cell walls, thus exhibiting its bacterial killing ability without the resistance issues associated with traditional antimicrobial agents.
Career Highlights
Throughout his career, Jung Min Kim has worked with various institutions, including the Kyungpook National University Industry-Academic Cooperation Foundation. His research and innovations have positioned him as a key figure in the fight against antibiotic resistance.
Collaborations
Jung Min Kim has collaborated with notable colleagues such as Jong Sook Jin and Shukho Kim. Their combined expertise has contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Jung Min Kim's innovative work in the field of antibacterial treatments showcases his commitment to addressing critical health challenges posed by antibiotic-resistant bacteria. His contributions are paving the way for new therapeutic options in the medical and biotechnology industries.